Eledon Pharmaceuticals, Inc.
Key Metrics
- Previous Close
- $3.55
- 52-Week Range
- $1.35 – $4.60
- Market Cap
- $286.04M
- P/E (TTM)
- —
- EPS (TTM)
- -0.90
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 2.66
- PEG Ratio
- —
- Return on Equity
- -110.71%
- Return on Assets
- -39.02%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 7.90
- Debt/Equity
- 0.01
- Total Debt
- $467.00K
- Free Cash Flow
- $-45.10M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $197.75M
Market Snapshot
About
Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for people requiring organ or cell-based transplants and for people with autoimmune and inflammatory diseases. The company's lead product candidate, tegoprubart, is a monoclonal antibody targeting CD40 Ligand, a key mediator of immune activation. Eledon is conducting clinical trials evaluating tegoprubart in kidney transplant recipients and in amyotrophic lateral sclerosis (ALS). The company's scientific approach aims to address the limitations of current immunosuppressive therapies by providing more selective immune modulation.